Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2014 Jan 8;9(1):e85694.
doi: 10.1371/journal.pone.0085694. eCollection 2014.

"V体育官网入口" Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome

Dongying Zhao  1 , Lianshu Han  1 , Zhengjuan He  1 , Jun Zhang  2 , Yongjun Zhang  2
Affiliations

Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome

"V体育2025版" Dongying Zhao et al. PLoS One. .

V体育安卓版 - Abstract

Early detection is the most effective way to improve the clinical outcome of biliary atresia (BA). Emerging metabolomics provides a powerful platform for discovering novel biomarkers and biochemical pathways to improve early diagnosis. The aim of this study is to find the potential biomarkers to distinguish BA from neonatal hepatitis syndrome (NHS) by using a metabolomics method VSports手机版. We comprehensively analyzed the serum metabolites in a total of 124 blood samples from patients with BA or neonatal hepatitis syndrome (NHS) and from normal individuals using advanced metabolomic approaches, and found that the levels of glutarylcarnitine (C5DC) significantly increased in the BA group while the levels of threonine (Thr) significantly rose in the NHS group comparing with the other groups. The levels of glutamic acid (Glu) in the BA group were significantly elevated compared to those in the NHS group, but still lower than the hyperbilirubinemia and normal controls. The levels of propionyl carnitine (C3), isovaleryl carnitine (C5) and glutamine (Gln) were reduced in the BA group compared to those in the NHS group, but still higher than the hyperbilirubinemia and normal controls. This study demonstrates the possibility of metabolomics as non-invasive biomarkers for the early detection of BA and also provides new insight into pathophysiologic mechanisms for BA. .

PubMed Disclaimer

V体育官网入口 - Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. A typical LC-MS/MS spectrum of blood spots from patients.
Blood samples were prepared and mass spectrometric analysis of individual sample was performed as described in “Methods” in details. Panel A shows a mass spectrum was acquired in the neutral loss scan mode. The scan was range from m/z 140 to m/z 280. It can detect most of the amino acids. Panel B shows a mass spectrum was acquired in the multiple reaction monitor mode. It was mainly used to detect Gly, Orn, Arg, Cit and its internal standard. Panel C shows a mass spectrum was acquired in precursor ion scanning mode. It used to detect the acylcarnitine in the sample.
Figure 2
Figure 2. OPLS-DA score scatter plots obtained from of LCMS analysis of samples.
A. OPLS-DA score plots of BA and normal; B. OPLS-DA score plots of with NHS and normal; C. OPLS-DA score plots of BA and NHS; D. OPLS-DA score plots of hyperbilirubinemia and normal. The fig. showing that the two populations are well separated respectively.
Figure 3
Figure 3. The amino acid and acylcarnitine with a VIP value above 1.0 were identified as markers to discriminate the two comparing group.
The Variables were aligned in descending order of their VIP values. From model A and model B, we can obtain the identified metabolites of BA and NHS. From model C, we can verify these metabolites obtained above can distinguish BA from NHS. From model D, we can exclude the interference of metabolites in hyperbilirubinemia infants.
See this image and copyright information in PMC

References

    1. Hartley JL, Davenport M, Kelly DA (2009) Biliary atresia. Lancet 374: 1704–1713. - PubMed
    1. Chardot C (2006) Biliary atresia. Orphanet J Rare Dis 1: 28. - PMC - PubMed
    1. Feldman AG, Mack CL (2012) Biliary atresia: cellular dynamics and immune dysregulation. Semin Pediatr Surg 21: 192–200. - PMC (VSports注册入口) - PubMed
    1. Moore SW, Zabiegaj-Zwick C, Nel E (2012) Problems related to CMV infection and biliary atresia. S Afr Med J 102: 890–892. - PubMed
    1. Szavay PO, Leonhardt J, Czech-Schmidt G, Petersen C (2002) The role of reovirus type 3 infection in an established murine model for biliary atresia. Eur J Pediatr Surg 12: 248–250. - PubMed (VSports最新版本)

Publication types

MeSH terms

VSports注册入口 - LinkOut - more resources